Prudential Financial Inc. lessened its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.0% in the 3rd quarter, Holdings Channel reports. The firm owned 124,687 shares of the biopharmaceutical company’s stock after selling 12,301 shares during the quarter. Prudential Financial Inc.’s holdings in Regeneron Pharmaceuticals were worth $55,750,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Fieldpoint Private Securities LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $130,000. FNY Partners Fund LP lifted its position in Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares during the last quarter. Vident Investment Advisory LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $200,000. Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $206,000. Finally, Moors & Cabot Inc. acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $217,000. 66.63% of the stock is owned by institutional investors and hedge funds.

A number of research firms have weighed in on REGN. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Barclays lowered shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $450.00 to $395.00 in a research report on Friday, October 20th. Oppenheimer reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Finally, Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $470.80.

Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $385.10 on Friday. Regeneron Pharmaceuticals Inc has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The stock has a market cap of $41,610.00, a PE ratio of 34.98, a PEG ratio of 1.44 and a beta of 1.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The business’s revenue was up 23.0% compared to the same quarter last year. equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/prudential-financial-inc-has-55-75-million-position-in-regeneron-pharmaceuticals-inc-regn/1797820.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.